Yariv Houvras, MD, PhD

Yariv Houvras, MD, PhD Specialties: Medical Oncology, Hematology/Oncology

Yariv Houvras, MD, PhD
Specialties: Medical Oncology, Hematology/Oncology
phone icon
checkmark iconAccepting new patients


1305 York Avenue
New York, NY 10021

insurance iconinsurance icon
Insurances Accepted

Please contact the doctor's office to verify that your insurance is accepted.

  • Affinity
  • Emblem Select Care
  • EmblemHealth HIP
  • Empire Blue Cross Blue Shield
  • Empire Blue Cross Blue Shield Healthplus
  • Fidelis Care
  • Group Health Incorporated
  • Healthfirst
  • Medicaid
  • Medicare
  • Oxford Health Plans
  • Rockefeller University - CoreSource
  • United Empire
  • UnitedHealthcare

about iconabout icon
About Yariv Houvras, MD, PhD

PROFESSIONAL TRAINING:Intern, Internal Medicine, Massachusetts General Hospital, 2001-02Resident, Internal Medicine, Massachusetts General Hospital, 2002-03Fellow, Hematology-Oncology, Dana Farber Cancer Institute, 2003-08Research Fellow, Boston Children’s Hospital, Leonard Zon Laboratory, 2005-10 Dr. Yariv Houvras is an internationally-renowned expert in the treatment and care of patients with advanced thyroid cancers, including differentiated thyroid cancer, papillary and follicular cancers, poorly differentiated, anaplastic and medullary thyroid cancers. Dr. Houvras is a physician-scientist with an active laboratory program to explore the genetic basis of tumor initiation and progression.Dr. Houvras leads a laboratory program utilizing zebrafish, a small freshwater fish, amenable to genetic studies. Work in the Houvras lab has led to new personalized models of cancer. These models are being tested to identify new treatments for patients with cancer. The zebrafish are also being used in drug discovery efforts to identify new inhibitors of cancer growth and metastasis.Dr. Houvras was recruited to Weill Cornell Medical College in 2011 and has served as Assistant Professor of Medicine in the Departments of Surgery and Medicine. He is a member of the Meyer Cancer Center and Cancer Genetics and Epigenetics Working Group. Dr. Houvras is the recipient of numerous awards and grants, including a K08 mentored physician-scientist award, an R21 from the NIH, and a tri-institutional drug discovery award to develop novel epigenetic inhibitors for cancer. He also serves on the board of the International Thyroid Oncology Group (ITOG), an interdisciplinary organization that coordinates clinical trials and translational studies in thyroid cancer.Dr. Houvras is a graduate of the University of Michigan (B.S. in Biology, 1992) and the MSTP program at Mount Sinai School of Medicine where he earned a combined MD/PhD degree (2001). Dr. Houvras was an intern and resident at Massachusetts General Hospital (MGH), and a fellow in Hematology-Oncology at the combined Dana-Farber/MGH program. He completed post-doctoral studies in cancer genetics at Boston Children's Hospital. He was recruited to Weill Cornell Medicine and NewYork-Presbyterian Hospital in 2011.

Hospital Affiliations

  • NewYork-Presbyterian / Weill Cornell Medical Center


  • Parathyroid Cancer

  • Solid Tumors

  • Thyroid Cancer


  • Fellowship: Dana Farber Cancer Institute
  • Internship: Massachusetts General Hospital
  • Medical School: Mount Sinai School of Medicine
  • Residency: Massachusetts General Hospital

Board Certifications

  • Hematology
  • Medical Oncology